Antiviral Therapy

Papers
(The TQCC of Antiviral Therapy is 4. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2020-10-01 to 2024-10-01.)
ArticleCitations
Journey of remdesivir from the inhibition of hepatitis C virus to the treatment of COVID-1915
EDP-514 in healthy subjects and nucleos(t)ide reverse transcriptase inhibitor-suppressed patients with chronic hepatitis B10
Tenofovir alafenamide fumarate10
Case study of hepatitis C virus control in Egypt: impact of access program9
JNJ-73763989 pharmacokinetics and safety: Liver-targeted siRNAs against hepatitis B virus, in Japanese and non-Japanese healthy adults, and combined with JNJ-56136379 and a nucleos(t)ide analogue in p9
HIV drug resistance in the era of contemporary antiretroviral therapy: A clinical perspective9
The transformation of HIV therapy: One pill once a day9
The best backbone for HIV prevention, treatment, and elimination: Emtricitabine+tenofovir7
Safety, tolerability, pharmacokinetics, and pharmacodynamics of oral JNJ-64794964, a TLR-7 agonist, in healthy adults7
The curing regimens of HCV: A SWOT analysis7
Hepatitis C virus/Hepatitis B virus coinfection: Current prospectives6
Polaris Observatory—supporting informed decision-making at the national, regional, and global levels to eliminate viral hepatitis5
Herpes simplex virus reactivation in patients with COVID-19 and acute respiratory distress syndrome: a prospective cohort study5
Computer-assisted drug discovery of potential natural inhibitors of the SARS-CoV-2 RNA-dependent RNA polymerase through a multi-phase in silico approach5
Letermovir use to treat complex cytomegalovirus reactivations in two heart transplant recipients5
Adefovir for lamivudine-resistant hepatitis B5
Efficacy of second-line dolutegravir plus 2 nucleoside reverse transcriptase inhibitors by baseline nucleoside reverse transcriptase inhibitor resistance and nucleoside reverse transcriptase inhibitor4
Cross-resistance to entry inhibitors and lenacapavir resistance through Week 52 in study CAPELLA4
A baseline model including quantitative anti-HBc to predict response of peginterferon in HBeAg-positive chronic hepatitis B patients4
Higher risk of mortality in HIV-HBV co-infected patients from sub-Saharan Africa is observed at lower CD4+ cell counts4
Impact of new cyclooxygenase 2 inhibitors on human cytomegalovirus replication in vitro4
Discovery and development of oseltamivir at Gilead Sciences4
Acquired HIV drug resistance among adults living with HIV receiving first-line antiretroviral therapy in Rwanda: A cross-sectional nationally representative survey4
Abstracts4
Antiretroviral therapy achieved metabolic complete remission of hepatic AIDS related Epstein-Barr virus-associated smooth muscle tumor4
Efficacy, safety and tolerability of Biktarvy in HIV-1 infection: A scoping review4
0.015960931777954